Guillermo Arreaza-Rubin, MD
NIDDK/NIH, Bethesda, Maryland, USA

As director for clinical immunology of diabetes program and the technologies for the diagnosis and diabetes control program, I oversee a variety of research projects designed to improve diagnosis, treatment and monitoring of this disease. My responsibilities include directing the Small Business Innovation Research/Small Business Technology Transfer Research (SBIR/STTR) program—which supports innovative research by small businesses that have the potential for commercialization—in areas related to immunology, diabetes and other endocrine and metabolic diseases. These areas include: drug discovery for diabetes and other endocrine diseases; new technologies for islet isolation, stem cell/regeneration, and transplantation; immune modulatory agents for the primary and secondary prevention of diabetes; inflammatory aspects of type 2 diabetes, insulin resistance, and obesity; and glucose control technologies. I oversee academic research on closed-loop systems/artificial pancreas development including novel glucose sensors and integrated pancreatic hormone replacement delivery technologies. My duties also include being program director for the Clinical Islet Transplantation (CIT) Consortium and the Clinical Islet Transplant Registry (CITR) acting as the executive secretary of the Clinical Islet Transplantation Consortium Data and Safety Monitoring Board. I also participate in the coordination of the new human islet research network (HIRN) program as a program director for the consortium for modeling autoimmunity (CMAI) and the consortium on human islet biomimetics (CHIB). I represent the NIDDK on several trans-NIH and interagency working groups on metabolic monitoring, inflammatory processes, autoimmunity and medical devices development and performance surveillance.